THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.

被引：0
|
作者：
Boone, E. C. [1 ]
Staggs, V. T. [1 ]
Pearce, R. E. [1 ]
Lata, R. F. [1 ]
Gaedigk, R. [1 ]
Jaime, L. K. Montane [2 ]
Cherner, M. [3 ]
Berard, A. [4 ]
Fridley, B. L. [5 ]
Dinh, J. C. [1 ]
Miller, N. A. [1 ]
Leeder, J. [1 ]
Gaedigk, A. [1 ]
机构：
[1] Childrens Mercy Kansas City, Kansas City, MO USA
[2] Int Inst Hlth Care Profess, Boca Raton, FL USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Montreal, Montreal, PQ, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-055
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] Role of CYP2D6 in the demethylation of fluoxetine in vivo
    Hamelin, BA
    Turgeon, J
    Vallee, F
    Belanger, PM
    Paquet, F
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI33 - PI33
  • [22] Investigation of terbinafine as a CYP2D6 inhibitor in vivo
    Abdel-Rahman, SM
    Gotschall, RR
    Kauffman, RE
    Leeder, JS
    Kearns, GL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) : 465 - 472
  • [23] Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo
    Ozdemir, V
    Naranjo, CA
    Shulman, RW
    Herrmann, N
    Sellers, EM
    Reed, K
    Kalow, W
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 198 - 207
  • [24] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [25] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [26] New aQTL SNPs for the CYP2D6 Identified by a Novel Mediation Analysis of Genome-Wide SNP Arrays, Gene Expression Arrays, and CYP2D6 Activity
    Jiang, Guanglong
    Chakraborty, Arindom
    Wang, Zhiping
    Boustani, Malaz
    Liu, Yunlong
    Skaar, Todd
    Li, Lang
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [27] In vivo indices of enzyme activity:: the effect of renal impairment on the assessment of CYP2D6 activity
    Rostami-Hodjegan, A
    Funck-Brentano, C
    Kroemer, HK
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 577 - 578
  • [28] CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
    Ratain, M. J.
    Nakamura, Y.
    Cox, N. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 184 - 186
  • [29] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Doki, Kosuke
    Sekiguchi, Yukio
    Kuga, Keisuke
    Aonuma, Kazutaka
    Homma, Masato
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 257 - 262
  • [30] Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6
    T. Bergmann
    L. Bathum
    K. Brosen
    European Journal of Clinical Pharmacology, 2001, 57 : 123 - 127
12345